$BLCO.TO

Bausch + Lomb Launching Triple Care Preservative Free Lubricant Eye Drops in the United States

Bausch + Lomb Swings to Q1 Adjusted Profit, Revenue up

Bausch + Lomb (BLCO.TO) reported a swing to first-quarter adjusted earnings as revenue rose slightly, the company said on Wednesday.The company reported adjusted earnings of US$19 million, or US$0.05 per share, meeting the consensus analyst forecast of US$0.05 per share, according to FactSet. Bausch + Lomb reported an adjusted loss of US$54 million, or US$0.15 per share, in the prior year period.Total reported revenue rose 9% to US$1.24 billion over the same period, beating the US$1.22 billion forecast. The company reported increased sales in all segments, with 14% revenue growth in pharmaceuticals led by higher sales for prescription dry eye treatments Miebo and Xiidra.Bausch + Lomb raised its 2026 revenue guidance to US$5.42 billion to US$5.52 billion, from the previous guidance of US$5.375 billion to US$5.475 billion.The company also guided to a slight increase in adjusted EBITDA for 2026 to US$1.01 billion to US$1.06 billion, from US$1.0 billion to US$1.05 billion.Bausch + Lomb shares closed down $0.07, to $21.58 on Tuesday, on the Toronto Stock Exchange.

Bausch + Lomb Q1 Revenue of US$1.244 Billion; Raises Guidance Based on Strong Performance and Positive Outlook